Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GSK Arexvy protects from RSV over 3 full seasons
GSK Arexvy protects from RSV over three full seasons
GSK (NYSE:GSK) announced Tuesday that Arexvy, a Phase 3 trial for its FDA-approved vaccine against Respiratory Syncytial Virus (RSV), generated protection against the virus over three full seasons in adults aged 60 years and older.
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy
GSK plc GSK announced new data from the phase III AReSVi-006 (Adult Respiratory Syncytial Virus) study. The study evaluated the efficacy of a single dose of its respiratory syncytial virus (RSV) vaccine,
GSK touts 3-year data on RSV shot Arexvy after CDC's narrower usage recommendation
While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case for its first-to-market respiratory syncytial virus (RSV) shot Arexvy. | GSK on Tuesday unveiled fresh data from the late-stage AReSVi-006 study of Arexvy in RSV-triggered lower respiratory tract disease in older adults over the span of three full RSV seasons.
GSK hopes for Arexvy boost after positive Phase III data
GSK shared new Phase III data on Arexvy, its RSV vaccine, at the 2024 CHEST annual meeting. Results show a single dose of Arexvy maintains 62.9% efficacy in preventing RSV-related lower respiratory tract disease (LRTD) and 67.
GSK says RSV vaccine protects against disease over three seasons
Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.
GSK Announces Positive Data From AReSVi-006 Phase III Trial For RSV Vaccine Arexvy
GSK plc (GSK, GSK.L) announced Tuesday new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons
GSK’s RSV vaccine is the only RSV vaccine with efficacy and safety data available through three full seasons, including in people at increased risk Safety and reactogenicity data are consistent ...
GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting
GSK presents positive data from AReSVi-006 phase III trial of respiratory syncytial virus vaccine, Arexvy at CHEST 2024 annual meeting: London, UK Wednesday, October 9, 2024, 14:0
GSK reports positive findings from Phase III RSV vaccine trial
The vaccine demonstrated efficacy across different respiratory syncytial virus (RSV) subtypes in older adults between the ages of 70 and 79 years.
McKnight's Long-Term Care News
4d
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
4d
GSK RSV shot 43% effective against severe disease in third year
GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Trending now
Soldier sentenced to 14 yrs
How to help Milton victims
Toxic mushrooms poison 11
Dems shut down AZ office
Oklahoma mass shooting
Tour guide killed in mine
Releases medical report
Admonishes Black men
Airstrikes hit ISIS camps
Gators displaced by Milton
Gets Walk of Fame star
Adds 8 new destinations
Russia cements ties with Iran
Dodgers advance to NLCS
CA rejects SpaceX plan
Calls for relief funding
To close 444 stores
Fidelity data breach
FTX exec heads to prison
Assets hit $11.5 trillion
Drug for hemophilia approved
Israeli strikes in Gaza
Gets 2 years for role in riot
Loses bid to get on PA ballot
Files suit against Virginia
To cut workforce by 10%
Expands sanctions on Iran
JPMorgan says soft landing
FAA OKs Starship 5 launch
S&P 500, Dow hit records
Feedback